Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment
Tweet Send to a Friend
Bayer announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application and granted priority review designation ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


